In the CLEAR SYNERGY trial, routine spironolactone after myocardial infarction did not reduce cardiovascular AEs in patients ...

Researchers compared rates of gout medication initiation among patients with gout and type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for ...

The literature increasingly acknowledges the role of inflammation in the development of atherosclerosis. Colchicine, a potent anti-inflammatory drug commonly used to treat gout and pericarditis, is ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...